Barrow Hanley Mewhinney & Strauss LLC reduced its stake in Sanofi (NASDAQ:SNY – Free Report) by 86.3% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 366,396 shares of the company’s stock after selling 2,314,577 shares during the period. Barrow Hanley Mewhinney & Strauss LLC’s holdings in Sanofi were worth $15,107,000 at the end of the most recent quarter.
A number of other institutional investors have also made changes to their positions in the stock. Ritholtz Wealth Management increased its stake in shares of Sanofi by 48.3% in the 3rd quarter. Ritholtz Wealth Management now owns 45,685 shares of the company’s stock valued at $1,884,000 after acquiring an additional 14,880 shares during the last quarter. Tidal Investments LLC boosted its stake in Sanofi by 21.5% during the 2nd quarter. Tidal Investments LLC now owns 165,289 shares of the company’s stock worth $7,051,000 after acquiring an additional 29,283 shares during the last quarter. Mondrian Investment Partners LTD grew its holdings in Sanofi by 2.3% during the third quarter. Mondrian Investment Partners LTD now owns 5,652,139 shares of the company’s stock valued at $233,038,000 after purchasing an additional 129,575 shares during the period. Archford Capital Strategies LLC acquired a new stake in Sanofi in the second quarter worth $1,417,000. Finally, Leo Wealth LLC acquired a new stake in Sanofi in the third quarter worth $1,033,000. 14.03% of the stock is owned by institutional investors and hedge funds.
Sanofi Trading Up 1.0%
NASDAQ SNY opened at $46.52 on Friday. The stock has a market capitalization of $112.78 billion, a price-to-earnings ratio of 23.03, a PEG ratio of 1.27 and a beta of 0.31. The stock’s 50 day moving average price is $43.08 and its two-hundred day moving average price is $44.38. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.27 and a current ratio of 1.12. Sanofi has a 52 week low of $39.07 and a 52 week high of $50.60.
Recent Sanofi Headlines
These are some of the SNY headlines that stood out recently:
- Positive Sentiment: Deutsche Bank reportedly assigned Sanofi a Buy rating, adding a favorable analyst view. Article: Sanofi Receives a Buy from Deutsche Bank
- Neutral Sentiment: Sanofi is reportedly evaluating an acquisition of Insmed, a biotech valued at roughly $26 billion. A deal could add to Sanofi’s pipeline, but analysts are divided over whether the strategic gains would justify the financial strain. Article: Potential Sanofi-Insmed Deal
- Negative Sentiment: A shortage of Sanofi’s Pompe disease drugs has persisted for more than three months, with some patients missing critical infusions. The company attributed the disruption to manufacturing issues at its Ireland facility, raising concerns about patient access and execution. Article: Pompe Drug Shortage Leaves Patients Struggling to Get Treatments
Analyst Ratings Changes
Several brokerages have issued reports on SNY. Jefferies Financial Group restated a “buy” rating on shares of Sanofi in a report on Thursday, October 1st. DZ Bank reiterated a “buy” rating on shares of Sanofi in a report on Friday, July 31st. Deutsche Bank reiterated a “buy” rating on shares of Sanofi in a report on Tuesday, September 29th. Weiss Ratings upgraded Sanofi from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday. Finally, HSBC reissued a “buy” rating on shares of Sanofi in a research note on Thursday, September 10th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and twelve have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Sanofi presently has an average rating of “Hold” and a consensus price target of $53.00.
View Our Latest Stock Report on Sanofi
About Sanofi
Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines. The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world. Sanofi traces its origins to a company established in France in 1973.
Read More
- Five stocks we like better than Sanofi
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Free Report).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.
